肝细胞癌组织中MEG3基因启动子甲基化状态及其临床意义

Promoter methylation of MEG3 gene in hepatocellular carcinoma and its clinical significance

目的探讨肝细胞癌组织中MEG3基因启动子的甲基化水平及其临床意义。方法利用甲基化特异性聚合酶链反应（MSP），检测2014年12月至2016年12月山西省肿瘤医院58例肝细胞癌及20例正常肝脏石蜡包埋组织中MEG3基因启动子的甲基化水平，并分析甲基化状态与患者临床病理特征间的关系。结果肝细胞癌组织中MEG3基因启动子甲基化发生率为55.2%（32/58），高于正常肝脏组织中的25.0%（5/20），两者差异有统计学意义（χ^2=6.72，P=0.02）。不同年龄、性别、甲胎蛋白水平、肿瘤数量和分化程度患者的MEG3基因启动子甲基化发生率比较，差异均无统计学意义（均P〉0.05）；不同肿瘤直径、是否肝硬化、乙型肝炎表面抗原（HBsAg）是否阳性、不同TNM分期和有无远处转移患者的MEG3基因启动子甲基化发生率比较，差异均有统计学意义（均P〈0.05）。结论MEG3基因启动子异常甲基化可能与肝细胞癌的发生相关，且与肿瘤直径、肝硬化、HBsAg、TNM分期和远处转移有关。

Objective To investigate promoter methylation state of MEG3 gene in hepatocellular carcinoma and its clinical significance.Methods Methylation-specific polymerase chain reaction （MSP） was performed to detect methylation of MEG3 promoter in 58 cases of hepatocellular carcinoma tissues and 20 cases of normal control from December 2014 to December 2016 in Shanxi Provincial Cancer Hospital, and to analyze the relationship between methylation and the clinicopathological features of the patients.Results The methylation incidence rate of MEG3 promoter in hepatocellular carcinoma tissues （55.2%, 32/58） was higher than that in normal liver tissue （25.0%, 5/20）, and there was a significant statistical difference （χ^2= 6.72, P= 0.02）. There was no significant difference in the incidence of MEG3 methylation of the patients with different age, gender, α-fetoprotein levels, tumor number and differentiation （all P 〉 0.05）. There was a significant difference in the incidence of MEG3 methylation of the patients with different tumors diameter, liver cirrhosis, hepatitis B surface antigen （HBsAg）, TNM staging and distant metastasis （all P 〈 0.05）.Conclusion Aberrant promoter methylation in MEG3 genes may be associated with the occurrence of hepatocellular carcinoma, tumor diameter, liver cirrhosis, HBsAg, TNM staging and distant metastasis.